297 related articles for article (PubMed ID: 33815613)
21. Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway.
Youssef RF; Cost NG; Darwish OM; Margulis V
Arab J Urol; 2012 Jun; 10(2):110-7. PubMed ID: 26558012
[TBL] [Abstract][Full Text] [Related]
22. Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.
Xu F; Na L; Li Y; Chen L
Cell Biosci; 2020; 10(1):54. PubMed ID: 32266056
[TBL] [Abstract][Full Text] [Related]
23. Targeting mTOR in renal cell carcinoma.
Hudes GR
Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
[TBL] [Abstract][Full Text] [Related]
24. The applicability of mTOR inhibition in solid tumors.
Konings IR; Verweij J; Wiemer EA; Sleijfer S
Curr Cancer Drug Targets; 2009 May; 9(3):439-50. PubMed ID: 19442061
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin regulates cell autophagy in endometrial cancer cells via the PI3K/AKT/mTOR signalling pathway.
Lin Q; Wang Y; Chen D; Sheng X; Liu J; Xiong H
Oncol Lett; 2017 May; 13(5):3567-3571. PubMed ID: 28521459
[TBL] [Abstract][Full Text] [Related]
26. PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy.
Luo Q; Du R; Liu W; Huang G; Dong Z; Li X
Front Oncol; 2022; 12():852383. PubMed ID: 35392233
[TBL] [Abstract][Full Text] [Related]
27. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
28. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies-New Therapeutic Possibilities.
Wiese W; Barczuk J; Racinska O; Siwecka N; Rozpedek-Kaminska W; Slupianek A; Sierpinski R; Majsterek I
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958470
[TBL] [Abstract][Full Text] [Related]
29. Targeting mTOR in cancer: renal cell is just a beginning.
Azim H; Azim HA; Escudier B
Target Oncol; 2010 Dec; 5(4):269-80. PubMed ID: 20563661
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.
Kim J; Jonasch E; Alexander A; Short JD; Cai S; Wen S; Tsavachidou D; Tamboli P; Czerniak BA; Do KA; Wu KJ; Marlow LA; Wood CG; Copland JA; Walker CL
Clin Cancer Res; 2009 Jan; 15(1):81-90. PubMed ID: 19118035
[TBL] [Abstract][Full Text] [Related]
31. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
Reddy GK; Mughal TI; Rini BI
Clin Genitourin Cancer; 2006 Sep; 5(2):110-3. PubMed ID: 17026798
[TBL] [Abstract][Full Text] [Related]
32. Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects.
Stanciu S; Ionita-Radu F; Stefani C; Miricescu D; Stanescu-Spinu II; Greabu M; Ripszky Totan A; Jinga M
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077529
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
Wang Q; Zhang X; Song X; Zhang L
Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
[TBL] [Abstract][Full Text] [Related]
34. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
Yu L; Wei J; Liu P
Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
[TBL] [Abstract][Full Text] [Related]
35. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
36. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma.
Campbell L; Jasani B; Edwards K; Gumbleton M; Griffiths DF
Br J Cancer; 2008 Mar; 98(5):931-40. PubMed ID: 18283322
[TBL] [Abstract][Full Text] [Related]
37. Bufalin suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway.
Xie J; Lin W; Huang L; Xu N; Xu A; Chen B; Watanabe M; Liu C; Huang P
Oncol Lett; 2018 Sep; 16(3):3867-3873. PubMed ID: 30128000
[TBL] [Abstract][Full Text] [Related]
38. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
[TBL] [Abstract][Full Text] [Related]
40. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.
Chamcheu JC; Roy T; Uddin MB; Banang-Mbeumi S; Chamcheu RN; Walker AL; Liu YY; Huang S
Cells; 2019 Jul; 8(8):. PubMed ID: 31370278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
